1990
1995 20
04
2005
Hybri
d-N
anoengin
eeri
ng™
2013
Lipi
d co
mpl
ex
PEG
com
plex
Poly
mer
s
Albu
min
Lowest or No upfront price
New technologyFastest resultsPatent protectionBranded guaranteeLow solubility is a common but a road blocker for
manyNovel drugs. Typically, companies will have a hit and trila Approach to solve your problem with huge upfront charges.
Introducing our newest Hybrid-Nanoengineering™ Technology to fix your solubility problem. You will not only have product but a patent protection and a branding for premium price of your product.
Just one statement!We will provide you the best productWith patent protection
Are you still looking for the long term investment
winner for the next decade?
• Only solution to win the race• Join us for that goal• Multiple location to conduct your project
Hybrid-Nanoengineering™
Meda Biotech llc.609-902-7128
A unique platform for nanomedicines
160 Nanomedicines Ready
A reliable solution for your success to resolve
solubility problem
Join us ToWin
NanotechnologyA solution for
solubility
Services with patent protection
One platform for all Nanoparticles for;
Increase bioavailability with efficacy and branding Scalable technology
Yes or No in three weeksNo charge for this work!
Meda Biotech llc. Nano Biotech4000 McHugh Rd. 426-B Focal PointZachary, LA70791 Amritsar, PunjabUSA India
www.nanomeda.comwww.nanosgroup.com
609-902-712891-9356408017
Meda's Hybrid-Nanoengineering™ drug delivery platform generates more commercial opportunities than we can pursue independently. Strategic partnering is therefore a critical component of our ability to advance Meda's novel therapeutics programs into clinical development and onto the market.
Meda’s objective is to selectively partner at strategic stages of the development process while retaining select therapeutic programs to develop independently. We want to strategically integrate our patented technology platform into the best possible companies to insure we achieve the most rapid development of therapeutics which utilize our base technology. This strategy will enable the Company to maximize the number of lead compounds it can rapidly put into development as it continues to harvest output and develop its platform to a higher degree of productivity. Meda pursues the following types of collaborations:
Licensing and/or co-development arrangements for our clinical pipeline products and pre-clinical drugs in development. Meda can collaborate to develop therapeutics from our existing programs of both proteins/peptides and small molecules. Partners may choose to advance these programs independently or in conjunction with Meda. Meda can take the newly developed molecules or existing patent expired drugs and put them in our platform to develop next generation of same drug to extent the further life the expired patented drug.
PartneringDual
Action
One broken part can mean total equipment failure. An imaging technology partner that quickly delivers the parts you need is a lifesaver, sometimes literally. But fast access isn’t enough—replacement parts also have to be quality assured and cost effective.Make us your next partner for nanomedicine and to resolve your;
BIOAVAILABILITY PROBLEM
160 molecules for clinical trials
Top Related